However, approximately 15% of patients with early stage HER2+ breast cancer experience recurrence after adjuvant trastuzumab therapy (4), and patients with advanced-stage HER2+ breast cancer who receive trastuzumab-based palliative therapy will inevitably experience disease progression within approximately 12 months (5). Here, ERBB2 is linked to breast carcinoma.